AI Engines For more Details: Perplexity Kagi Labs You
Immune Support: Cistus incanus is believed to have immunomodulatory effects, meaning it can help regulate and support the immune system. It may help enhance immune function, making the body more resilient to infections and illnesses.
Antioxidant Properties: Cistus incanus contains high levels of polyphenolic compounds, such as flavonoids and phenolic acids, which have strong antioxidant properties. These antioxidants help neutralize free radicals and reduce oxidative stress in the body, protecting cells from damage and supporting overall health.
Antimicrobial Activity: Cistus incanus has been shown to possess antimicrobial properties, inhibiting the growth of bacteria, viruses, and fungi. It may be used to prevent and treat infections, particularly respiratory infections such as colds, flu, and sinusitis.
Anti-inflammatory Effects: Cistus incanus exhibits anti-inflammatory properties, which may help reduce inflammation and alleviate symptoms of inflammatory conditions such as arthritis, rheumatism, and inflammatory bowel disease (IBD).
Digestive Health: Cistus incanus is often used to support digestive health and alleviate symptoms of gastrointestinal discomfort, such as indigestion, bloating, and gas. It may help stimulate digestion, soothe irritated stomach linings, and promote gastrointestinal comfort.
Skin Health: Some research suggests that Cistus incanus may have beneficial effects on skin health, including anti-aging and anti-inflammatory properties. It may help protect the skin from damage caused by UV radiation and environmental pollutants.
Respiratory Health: Cistus incanus has been traditionally used to support respiratory health and alleviate symptoms of respiratory infections, such as coughs, colds, bronchitis, and asthma. It may help relieve congestion, soothe irritated airways, and promote respiratory comfort.
Anticancer Potential: Preliminary studies have indicated that Cistus incanus extracts may have anticancer properties, inhibiting the growth and proliferation of cancer cells. Further research is needed to explore its potential as a natural cancer treatment or preventive agent.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Saccharomyces | Reduces |
| species | Bacillus subtilis | Reduces |
| species | Enterococcus faecium | Reduces |
| species | Escherichia coli | Reduces |
| species | Micrococcus luteus | Reduces |
| species | Saccharomyces cerevisiae | Reduces |
| subspecies | Bacillus subtilis subsp. natto | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.5 | 0.5 | |
| Acne | 1 | 1 | |
| ADHD | 0.5 | 0.5 | |
| Allergic Rhinitis (Hay Fever) | 2.1 | 0.5 | 3.2 |
| Allergies | 2.1 | 0.5 | 3.2 |
| Allergy to milk products | 0.5 | 0.6 | -0.2 |
| Alzheimer's disease | 1.5 | 0.6 | 1.5 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.9 | 0.5 | 0.8 |
| Ankylosing spondylitis | 1.6 | 1.6 | |
| Antiphospholipid syndrome (APS) | 0.5 | 0.5 | |
| Asthma | 3 | 0.5 | 5 |
| Atherosclerosis | 1.5 | 1.5 | |
| Atrial fibrillation | 0.5 | 0.6 | -0.2 |
| Autism | 2.7 | 1.6 | 0.69 |
| Autoimmune Disease | 0.6 | 0.6 | |
| benign prostatic hyperplasia | 0.6 | 0.6 | |
| Biofilm | 3.5 | 3.5 | |
| Bipolar Disorder | 0.6 | 0 | 0 |
| Brain Trauma | 0.5 | 0 | 0 |
| Breast Cancer | 0.5 | 0.5 | |
| Cancer (General) | 1.5 | -1.5 | |
| Carcinoma | 0.9 | 0.9 | |
| Celiac Disease | 2 | 2 | |
| Cerebral Palsy | 0.5 | 0.5 | |
| Chronic Fatigue Syndrome | 0.5 | 0 | 0 |
| Chronic Kidney Disease | 0.6 | 0.6 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 3 | 3 | |
| Chronic Urticaria (Hives) | 1.1 | 1.1 | |
| Coagulation / Micro clot triggering bacteria | 2.1 | 2.1 | |
| Cognitive Function | 0.3 | -0.3 | |
| Colorectal Cancer | 1.1 | 0.5 | 1.2 |
| Constipation | 0.6 | 0.6 | |
| Coronary artery disease | 1.1 | 1.1 | |
| COVID-19 | 5.6 | 1.9 | 1.95 |
| Crohn's Disease | 3.4 | 0.5 | 5.8 |
| Cushing's Syndrome (hypercortisolism) | 1.3 | 1.3 | |
| cystic fibrosis | 2.9 | 2.9 | |
| d-lactic acidosis (one form of brain fog) | 1 | 1 | |
| deep vein thrombosis | 2.1 | 0 | 0 |
| Denture Wearers Oral Shifts | 1.9 | 1.9 | |
| Depression | 2.4 | 1.1 | 1.18 |
| Dermatomyositis | 0.5 | 0.5 | |
| Eczema | 1.6 | 1.6 | |
| Endometriosis | 2 | 0.5 | 3 |
| Epilepsy | 1.1 | 1.1 | |
| erectile dysfunction | 0.6 | 0.6 | |
| Fibromyalgia | 0.5 | 0.5 | |
| Functional constipation / chronic idiopathic constipation | 1.6 | 1.6 | |
| gallstone disease (gsd) | 2.1 | 2.1 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.5 | 0.5 | |
| Generalized anxiety disorder | 1.1 | 1.1 | |
| Gout | 0.5 | 0.5 | |
| Hashimoto's thyroiditis | 0 | 0 | |
| Heart Failure | 2.6 | 2.6 | |
| Hidradenitis Suppurativa | 1 | 1 | |
| High Histamine/low DAO | 1 | 1 | |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.5 | 0 |
| hyperglycemia | 1.1 | 1.1 | |
| Hyperlipidemia (High Blood Fats) | 0 | 0 | |
| hypertension (High Blood Pressure | 1.1 | 0 | 0 |
| Hypothyroidism | 1 | 1 | |
| Hypoxia | 1.1 | 1.1 | |
| IgA nephropathy (IgAN) | 0.5 | 0 | 0 |
| Inflammatory Bowel Disease | 1.1 | 0.5 | 1.2 |
| Insomnia | 1 | 0.5 | 1 |
| Intelligence | 0.5 | 0.5 | |
| Irritable Bowel Syndrome | 2.1 | 0 | 0 |
| ischemic stroke | 1 | 0.6 | 0.67 |
| Juvenile idiopathic arthritis | 0.5 | 0.5 | |
| Liver Cirrhosis | 1.6 | 0.5 | 2.2 |
| Long COVID | 0.6 | 0.6 | |
| Lung Cancer | 0.6 | 0.6 | |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.6 | 1.6 | |
| ME/CFS with IBS | 0 | 0 | 0 |
| ME/CFS without IBS | 0 | 0 | 0 |
| Metabolic Syndrome | 1.6 | 0.5 | 2.2 |
| Mood Disorders | 1.4 | 1.1 | 0.27 |
| Multiple Sclerosis | 1.9 | 0.3 | 5.33 |
| myasthenia gravis | 0.6 | 0.6 | |
| Neuropathy (all types) | 0.6 | -0.6 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0.5 | 0.5 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.6 | 0.5 | 4.2 |
| Obesity | 2.6 | 0 | 0 |
| obsessive-compulsive disorder | 1.1 | 1.1 | |
| Osteoarthritis | 1.5 | 1.5 | |
| Osteoporosis | 1.1 | 1.1 | |
| pancreatic cancer | 0 | 0 | |
| Parkinson's Disease | 3 | 0.6 | 4 |
| Polycystic ovary syndrome | 0.6 | 0.6 | |
| Premenstrual dysphoric disorder | 0.3 | 0.3 | |
| primary biliary cholangitis | 0.5 | 0.5 | |
| Primary sclerosing cholangitis | 0.5 | 0.5 | |
| Psoriasis | 1.5 | 1.5 | |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.2 | 0 | 0 |
| Rosacea | 1 | 1 | |
| Schizophrenia | 1.5 | 0 | 0 |
| scoliosis | 1.5 | 1.5 | |
| sensorineural hearing loss | 1 | 1 | |
| Sjögren syndrome | 0.6 | 0.6 | |
| Sleep Apnea | 0.5 | 0.5 | |
| Slow gastric motility / Gastroparesis | 0.5 | 0.5 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.8 | 1.8 | |
| Stress / posttraumatic stress disorder | 0.5 | 0.5 | |
| Systemic Lupus Erythematosus | 2.1 | 2.1 | |
| Type 1 Diabetes | 1.6 | 0 | 0 |
| Type 2 Diabetes | 1.1 | 0.5 | 1.2 |
| Ulcerative colitis | 2.1 | 0 | 0 |
| Unhealthy Ageing | 0 | 0 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
